Myriad Genetics (MYGN) Change in Accured Expenses (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Change in Accured Expenses data on file, last reported at -$7.4 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$7.4 million, up 40.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.5 million (up 42.01% YoY), and the FY2025 annual result was -$27.5 million, up 32.93% from the prior year.
• Change in Accured Expenses declined to -$7.4 million in Q1 2026 per MYGN's latest filing, from -$6.7 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $71.9 million in Q2 2023 and troughed at -$59.4 million in Q4 2023.
• A 5-year average of -$7.9 million and a median of -$6.7 million in 2025 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 4340.0% in 2023 and fell as far as 2021.43% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$2.8 million in 2022, then sank by 2021.43% to -$59.4 million in 2023, then soared by 53.7% to -$27.5 million in 2024, then soared by 75.64% to -$6.7 million in 2025, then declined by 10.45% to -$7.4 million in 2026.
• Business Quant data shows MYGN's Change in Accured Expenses at -$7.4 million in Q1 2026, -$6.7 million in Q4 2025, and $8.4 million in Q3 2025.